Assessment of the Amc-Bioartificial Liver in the Anhepatic Pig1

Sosef, Meindert N.; Abrahamse, Leo S L; Kerkhove, Maarten-Paul van de; Hartman, Robin; Chamuleau, R. A. F. M.; Gulik, Thomas M. Van

doi:10.1097/00007890-200201270-00009

Cited by 60 publications

(42 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In many different models of ALF several BALs based on animal liver cells have shown to prolong survival significantly in comparison to standard treatment [23][24][25][26][27][28][29][30][31][32][33] .…”

Section: How Good Are Results In Experimental Animals?mentioning

confidence: 99%

Future of bioartificial liver support

Chamuleau¹

2009

WJGS

View full text Add to dashboard Cite

Many different artificial liver support systems (biological and non-biological) have been developed, tested preclinically and some have been applied in clinical trials. Based on theoretical considerations a biological artificial liver (BAL) should be preferred above the non-biological ones. However, clinical application of the BAL is still experimental. Here we try to analyze which hurdles have to be taken before the BAL will become standard equipment in the intensive care unit for patients with acute liver failure or acute deterioration of chronic liver disease.

show abstract

Section: How Good Are Results In Experimental Animals?mentioning

confidence: 99%

Future of bioartificial liver support

Chamuleau¹

2009

WJGS

View full text Add to dashboard Cite

show abstract

“…Brain autopsy was not performed. The remaining 10 animals were connected to the AMC-BAL for evaluation of its efficacy in the anhepatic pig as has been reported elsewhere [4].…”

Section: Resultsmentioning

confidence: 99%

Total Hepatectomy Model in Pigs: Revised Method for Vascular Reconstruction Using a Rigid Vascular Prosthesis

Sosef

Gulik²

2004

Eur Surg Res

View full text Add to dashboard Cite

Total hepatectomy in animals provides an irreversible model of acute liver failure. Vascular reconstruction in this model of acute liver failure was modified and characterized for the use of assessment of liver support systems. Pigs underwent total hepatectomy and a rigid three-way transparent polyethylene vascular conduit was used to replace the retrohepatic caval vein and to shunt the portal venous blood to the caval vein. Placement of the vascular conduit in conjunction with excision of the liver was completed in 10–22 min without the need of a temporary veno-venous bypass. A survival study conducted in 5 animals showed a mean survival time of 46 ± 6 h. Baseline and 4 h postoperative hemoglobin levels were not different, and plasma ammonia levels rose to more than 30-fold of baseline values. All animals died of cardiac arrhythmias and irreversible shock. Total hepatectomy in the pig using a three-way portal-venous conduit is a reliable and well-reproducible animal model of acute liver failure for evaluation of liver assist devices.

show abstract

“…[161][162][163][164] However, how to rationally design and perform the evaluation of the effectiveness of EBAL treatment remains a crucial issue in the clinical trials. Currently the survival of patients is the most commonly adopted indicator for the efficacy evaluation of EBAL, but once possible, according to the standard therapy, the ALF patients meeting the inclusion criteria of the clinical trials will move to undergo liver transplant only after a short term of EBAL treatment, and the survival is dominantly determined by the surgery effect; thus it is difficult to identify whether the survival improvement is due to EBAL or liver transplantation.…”

Section: F Radial-flow Bioreactor Bioartificial Livermentioning

confidence: 99%

Current development of bioreactors for extracorporeal bioartificial liver (Review)

et al. 2010

View full text Add to dashboard Cite

The research and development of extracorporeal bioartificial liver is gaining pace in recent years with the introduction of a myriad of optimally designed bioreactors with the ability to maintain long-term viability and liver-specific functions of hepatocytes. The design considerations for bioartificial liver are not trivial; it needs to consider factors such as the types of cell to be cultured in the bioreactor, the bioreactor configuration, the magnitude of fluid-induced shear stress, nutrients' supply, and wastes' removal, and other relevant issues before the bioreactor is ready for testing. This review discusses the exciting development of bioartificial liver devices, particularly the various types of cell used in current reactor designs, the state-of-the-art culturing and cryopreservation techniques, and the comparison among many today's bioreactor configurations. This review will also discuss in depth the importance of maintaining optimal mass transfer of nutrients and oxygen partial pressure in the bioreactor system. Finally, this review will discuss the commercially available bioreactors that are currently undergoing preclinical and clinical trials.

show abstract

Assessment of the Amc-Bioartificial Liver in the Anhepatic Pig1

Cited by 60 publications

References 30 publications

Future of bioartificial liver support

Future of bioartificial liver support

Total Hepatectomy Model in Pigs: Revised Method for Vascular Reconstruction Using a Rigid Vascular Prosthesis

Current development of bioreactors for extracorporeal bioartificial liver (Review)

Contact Info

Product

Resources

About